Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on December 13, 2017. The filing addresses corporate governance changes, specifically the appointment of a new director and the resignation of an existing director, effective December 31, 2017, and January 1, 2018, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Director: Stefano Ferrari resigned from the Board of Directors, effective December 31, 2017. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Appointment of New Director: Matthew Wikler was appointed to fill the vacant director position created by Mr. Ferrari's resignation, effective January 1, 2018. Dr. Wikler will serve until the next annual meeting of shareholders or until a successor is elected.
- Committee Assignment: Dr. Wikler has been appointed to serve on the Compensation Committee effective January 1, 2018.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations or risks. The primary commentary relates to Dr. Wikler's extensive background in infectious disease technology, regulatory affairs, and pharmaceutical leadership, including prior roles at The Medicines Company, Rib-X Pharmaceuticals, and the FDA.
Compensation Arrangements: Dr. Wikler's compensation includes:
- Annual cash retainer fee of $50,000.
- Annual cash fee of $6,000 for serving on the Compensation Committee.
- Annual stock option grant valued at $80,000 (determined by Black-Scholes method).
- Initial option grant to purchase 150,000 shares of common stock upon joining the Board.
- Option to receive annual retainer and committee fees in unrestricted shares of common stock in lieu of cash.
Important Facts for Investor Verification
- Verify the effective dates of the director transition (Ferrari: Dec 31, 2017; Wikler: Jan 1, 2018).
- Confirm the total equity grant size for the new director (150,000 shares initial grant plus annual grants).
- Review the Company's amended and restated non-employee director compensation policy for full terms.
- Check for any subsequent filings regarding the outcome of the next annual shareholder meeting regarding Dr. Wikler's election.